samedan logo
 
 
 
spacer
home > ebr > summer 2004 > editor's letter
PUBLICATIONS
European Biopharmaceutical Review

Editor's Letter

As we bring you the summer issue of EBR, there appear to be guarded grounds for continued optimism towards an upswing in the European biotechnology industry. As evidenced by the upbeat mood of the US industry at the recent Annual BIO Convention, this new optimism seems to be based on tangible measures of an industry regaining its feet. For example, increasing numbers of biologic drugs (25 out of 37) approved by the FDA in 2003, coupled to decreasing product review timeframes by the FDA, led to renewed investor interest and the second most successful financing year in the US industry's history in 2003 ($19 billion in public and private funds). However, the situation in Europe isn't quite that rosy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott, Technology Consultant at London Technology Network
spacer
Dr Helen Abbott
spacer
spacer
spacer
Lucy George
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics closes a $40 million funding round led by Sofinnova Partners and Redmile Group

Cambridge, UK, 28 October 2021: Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million (circa 30 million) investment round. The round was led by Sofinnova Partners (Paris, France) and Redmile Group (San Francisco, USA) co-investing on equal terms.
More info >>

White Papers

The Key To Tableting Success: How To Choose The Right Tooling

Natoli Engineering Company, Inc.

Choosing the right tooling can increase tablet output, decrease waste and ultimately determine the success of a product launch.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement